MA45280A - Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation - Google Patents

Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation

Info

Publication number
MA45280A
MA45280A MA045280A MA45280A MA45280A MA 45280 A MA45280 A MA 45280A MA 045280 A MA045280 A MA 045280A MA 45280 A MA45280 A MA 45280A MA 45280 A MA45280 A MA 45280A
Authority
MA
Morocco
Prior art keywords
antibulin
methods
drug conjugates
based drug
conjugates
Prior art date
Application number
MA045280A
Other languages
English (en)
Other versions
MA45280B1 (fr
Inventor
Earl F Albone
Xin Cheng
Daniel W Custar
Keiji Furuuchi
Jing Li
Utpal Majumder
Toshimitsu Uenaka
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MA45280A publication Critical patent/MA45280A/fr
Publication of MA45280B1 publication Critical patent/MA45280B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA45280A 2016-03-02 2017-03-02 Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation MA45280B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662302562P 2016-03-02 2016-03-02
PCT/US2017/020529 WO2017151979A1 (fr) 2016-03-02 2017-03-02 Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
MA45280A true MA45280A (fr) 2019-01-09
MA45280B1 MA45280B1 (fr) 2021-08-31

Family

ID=58347964

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45280A MA45280B1 (fr) 2016-03-02 2017-03-02 Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation

Country Status (35)

Country Link
US (4) US10548986B2 (fr)
EP (2) EP3423105B1 (fr)
JP (6) JP6599019B2 (fr)
KR (4) KR20220101204A (fr)
CN (4) CN108883198B (fr)
AR (3) AR107787A1 (fr)
AU (3) AU2017225982B2 (fr)
BR (1) BR112018067379A2 (fr)
CA (1) CA3013791A1 (fr)
CL (3) CL2018002456A1 (fr)
CO (1) CO2018008667A2 (fr)
CY (1) CY1124628T1 (fr)
DK (1) DK3423105T3 (fr)
ES (1) ES2880402T3 (fr)
HR (1) HRP20211125T1 (fr)
HU (1) HUE054726T2 (fr)
IL (3) IL292946B2 (fr)
JO (3) JOP20170053B1 (fr)
LT (1) LT3423105T (fr)
MA (1) MA45280B1 (fr)
MD (1) MD3423105T2 (fr)
MX (4) MX2018010562A (fr)
MY (2) MY199595A (fr)
PE (3) PE20231049A1 (fr)
PH (1) PH12018501847A1 (fr)
PL (1) PL3423105T3 (fr)
PT (1) PT3423105T (fr)
RS (1) RS62108B1 (fr)
RU (1) RU2754369C2 (fr)
SG (2) SG10202007520WA (fr)
SI (1) SI3423105T1 (fr)
SM (1) SMT202100416T1 (fr)
TW (3) TWI871094B (fr)
UA (1) UA125024C2 (fr)
WO (1) WO2017151979A1 (fr)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006241099B2 (en) * 2005-04-22 2012-04-19 Eisai, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
TWI769982B (zh) * 2015-06-24 2022-07-11 日商Ｊｃｒ製藥股份有限公司 通過血腦障壁之抗人類運鐵蛋白受體抗體
CA2990565A1 (fr) 2015-06-24 2016-12-29 Jcr Pharmaceuticals Co., Ltd. Proteine de fusion contenant un bdnf et un anticorps du recepteur de la transferrine anti-humain
CN109983031B (zh) 2016-12-26 2022-11-25 Jcr制药股份有限公司 通过血脑屏障的新的抗人转铁蛋白受体抗体
KR102573622B1 (ko) 2016-12-26 2023-08-31 제이씨알 파마 가부시키가이샤 Bdnf를 포함하는 융합 단백질
JP7168580B2 (ja) 2017-04-05 2022-11-09 プレジデント アンド フェローズ オブ ハーバード カレッジ 大環状化合物およびその使用
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
IL295588B2 (en) 2017-07-06 2024-03-01 Harvard College Synthesis of halichondrins
KR102771546B1 (ko) * 2017-11-08 2025-02-21 야페이 상하이 바이오로지 메디신 사이언스 앤드 테크놀로지 컴퍼니 리미티드 생체분자의 컨쥬게이트 및 이의 용도
ES2974243T3 (es) 2017-11-15 2024-06-26 Harvard College Compuestos macrocíclicos y usos de los mismos
WO2019232449A1 (fr) 2018-06-01 2019-12-05 Eisai R&D Management Co., Ltd. Conjugués anticorps-médicament modulateurs d'épissage et procédés d'utilisation
JP7346466B2 (ja) 2018-06-01 2023-09-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 スプライシング調節薬の使用方法
EP3834843A4 (fr) * 2018-08-06 2022-05-11 Daiichi Sankyo Company, Limited Association d'un conjugué anticorps-médicament et d'un inhibiteur de tubuline
BR112021010936A2 (pt) 2018-12-13 2021-08-31 Eisai R&D Management Co., Ltd. Conjugados anticorpo-fármaco de herboxidieno e métodos de uso
KR20240052881A (ko) * 2018-12-21 2024-04-23 노파르티스 아게 Pmel17에 대한 항체 및 이의 접합체
CN110568121A (zh) * 2019-07-11 2019-12-13 山东省药学科学院 一种艾日布林及含艾日布林的制剂中有关物质的检测方法
JP7657213B2 (ja) 2019-11-07 2025-04-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗メソテリンエリブリン抗体－薬物コンジュゲート及び使用方法
CN114828895A (zh) * 2019-12-23 2022-07-29 卫材R&D管理有限公司 制备基于艾日布林的抗体-药物缀合物的方法
AU2021210079A1 (en) 2020-01-22 2022-08-25 Jiangsu Hengrui Medicine Co., Ltd. Drug conjugate of Eribulin derivative, preparation method therefor and application thereof in medicine
CN113274507B (zh) * 2020-02-20 2025-02-28 亚飞（上海）生物医药科技有限公司 靶向递送和激活的免疫刺激性偶联复合物的制备和用途
CN113509557A (zh) * 2020-04-09 2021-10-19 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
TWI901692B (zh) 2020-06-05 2025-10-21 日商衛材R&D企管股份有限公司 抗ｂｃｍａ抗體-藥物軛合物及其使用方法
KR102810379B1 (ko) * 2020-08-07 2025-05-21 주식회사 피노바이오 데옥시사이티딘계 항암제 및 실릴 에테르 함유 링커를 포함하는 접합체 및 이의 용도
WO2022056278A1 (fr) * 2020-09-11 2022-03-17 Alexion Pharmaceuticals, Inc. Anticorps anti-céruloplasmine et leurs utilisations
EP4217009A4 (fr) * 2020-09-28 2025-09-24 Navrogen Inc Composition et utilisation d'anticorps anti-mésothéline formatés autrement, dans le traitement du cancer
WO2022082068A1 (fr) * 2020-10-18 2022-04-21 Ardeagen Corporation Agents de liaison anti-msln, leurs conjugués et leurs procédés d'utilisation
CN114560940B (zh) * 2020-11-27 2023-07-14 缔码生物科技(武汉)有限公司 一种抗SIRPα兔重组单克隆抗体及其制备方法和应用
US20240100177A1 (en) * 2020-12-04 2024-03-28 Dyne Therapeutics, Inc. Antibody-oligonucleotide complexes and uses thereof
WO2021115497A2 (fr) * 2020-12-08 2021-06-17 和铂医药(上海)有限责任公司 Conjugué protéine-médicament et procédé de conjugaison spécifique à un site
US20230390411A1 (en) * 2021-01-28 2023-12-07 Nanjing Chempion Biotechnology Co., Ltd. Conjugate and use thereof
JP2024504454A (ja) * 2021-01-29 2024-01-31 上▲海▼翰森生物医▲薬▼科技有限公司 抗体－薬物コンジュゲート及びその医学的使用
CA3215049A1 (fr) * 2021-04-10 2022-10-13 Baiteng ZHAO Agents de liaison a folr1, conjugues de ceux-ci et leurs procedes d'utilisation
EP4349371A4 (fr) * 2021-06-02 2025-06-25 Bio-Thera Solutions, Ltd. Conjugué de médicament et utilisation associée
CA3225975A1 (fr) * 2021-07-22 2023-01-26 Shanghai Senhui Medicine Co., Ltd. Conjugue de medicament de derive d'eribuline
EP4385522A1 (fr) * 2021-08-13 2024-06-19 Kunshan Xinyunda Biotech Co., Ltd. Conjugué anticorps-médicament à base d'inhibiteur de microtubules
JP2024532295A (ja) * 2021-08-24 2024-09-05 クンシャン シンユンター バイオテック カンパニー，リミティド 切断可能なリンカーを介して結合した抗体薬物複合体
CN115957339A (zh) * 2021-09-16 2023-04-14 正大天晴药业集团股份有限公司 抗体药物偶联物及其组合物和用途
WO2023055376A1 (fr) * 2021-09-30 2023-04-06 Virtuoso Binco, Inc. Anticorps multispécifiques pour cibler cd47 et icam1 et leurs procédés d'utilisation
WO2023061466A1 (fr) * 2021-10-14 2023-04-20 江苏恒瑞医药股份有限公司 Procédé de préparation d'un dérivé d'éribuline
WO2022078524A2 (fr) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Conjugaison spécifique d'un anticorps
WO2023098691A1 (fr) * 2021-12-01 2023-06-08 上海生物制品研究所有限责任公司 Conjugué anticorps-médicament et son utilisation
CN118401258A (zh) * 2021-12-09 2024-07-26 昆山新蕴达生物科技有限公司 一种亲和力改善的抗体-药物偶联物、其制备方法及应用
WO2023124963A1 (fr) * 2021-12-27 2023-07-06 昆山新蕴达生物科技有限公司 Conjugué anticorps-médicament ayant une réaction réversible réduite, procédé de préparation s'y rapportant et application associée
WO2023143319A1 (fr) * 2022-01-28 2023-08-03 启德医药科技（苏州）有限公司 Conjugué anticorps-médicament, composition pharmaceutique et leur utilisation
WO2023143320A1 (fr) * 2022-01-28 2023-08-03 博瑞生物医药（苏州）股份有限公司 Lieur pour la préparation d'un conjugué anticorps-médicament, composé et utilisation
EP4480499A1 (fr) * 2022-02-16 2024-12-25 Medilink Therapeutics (Suzhou) Co., Ltd. Conjugué d'anticorps-éribuline ou un dérivé de celui-ci, intermédiaire de celui-ci, son procédé de préparation, composition pharmaceutique de celui-ci et son utilisation
IL314828A (en) * 2022-03-11 2024-10-01 Mablink Bioscience Antibody-drug conjugates and their uses
CA3247662A1 (fr) * 2022-04-12 2023-10-19 Eisai R & D Management Co., Ltd. Conjugués anticorps-médicament à base d'éribuline et procédés d'utilisation
WO2023198079A1 (fr) * 2022-04-12 2023-10-19 百奥泰生物制药股份有限公司 Méthode de traitement d'une tumeur solide positive à her2
CN120417932A (zh) * 2022-10-14 2025-08-01 启德医药科技（苏州）有限公司 接头-有效载荷化合物、偶联物及其应用
CN117917248A (zh) * 2022-10-20 2024-04-23 英诺湖医药(杭州)有限公司 酶裂解连接子及包含其的配体-艾瑞布林偶联物
EP4619038A2 (fr) * 2022-11-14 2025-09-24 Cornell University Polypeptides à fonctionnalité anionique, ainsi que procédés de fabrication et utilisations y relatifs
KR20250133788A (ko) * 2023-01-17 2025-09-08 시스트이뮨, 인코포레이티드 에리불린 약물 접합체
WO2024153224A1 (fr) * 2023-01-19 2024-07-25 江苏恒瑞医药股份有限公司 Composition pharmaceutique contenant un conjugué de médicament dérivé de l'éribuline
JP2026505404A (ja) * 2023-02-13 2026-02-13 ブリス バイオファーマシューティカル（ハンゾウ）カンパニー，リミテッド がんの治療に使用される抗体－薬物複合体
WO2024235135A1 (fr) * 2023-05-12 2024-11-21 四川科伦博泰生物医药股份有限公司 Composé macrocyclique et son procédé de préparation et son utilisation
TW202448519A (zh) * 2023-05-12 2024-12-16 大陸商蘇州宜聯生物醫藥有限公司 多彈頭抗體偶聯藥物及其製備方法和用途
CN120957757A (zh) * 2023-05-12 2025-11-14 四川科伦博泰生物医药股份有限公司 大环类药物偶联物及其制备方法和用途
JP2024165695A (ja) 2023-05-18 2024-11-28 セイコーエプソン株式会社 印刷方法、印刷ヘッドユニットおよびロボットシステム
TW202513596A (zh) 2023-06-09 2025-04-01 大陸商徠特康（蘇州）生物製藥有限公司 抗ｈｅｒ２抗體、抗體－藥物偶聯物及其藥物組合物、藥盒、製備方法和用途
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
WO2025027529A1 (fr) 2023-07-31 2025-02-06 Advesya Conjugués médicament-anticorps anti-il-1rap et leurs procédés d'utilisation
WO2025078841A2 (fr) 2023-10-11 2025-04-17 Antikor Biopharma Limited Anticorps, conjugués et leurs utilisations
TW202530697A (zh) 2023-10-13 2025-08-01 日商衛材R&D企管股份有限公司 用於基於艾日布林之抗體－藥物結合物之生物標記及使用方法
WO2025081063A2 (fr) 2023-10-13 2025-04-17 Eisai R&D Management Co., Ltd. Métabolites à base de conjugués anticorps-médicaments
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
WO2025106586A1 (fr) * 2023-11-13 2025-05-22 Luxvitae Therapeutics Inc. Composés cétoniques macrocycliques et leurs applications
WO2025128837A1 (fr) * 2023-12-13 2025-06-19 Systimmune, Inc. Conjugué anticorps anti-claudine18.2-médicament camptothécine et son utilisation pharmaceutique
WO2025126157A1 (fr) 2023-12-15 2025-06-19 Advesya Domaines de liaison anti-il-1rap et conjugués anticorps-médicament associés
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
WO2025162492A1 (fr) * 2024-01-29 2025-08-07 甘李药业股份有限公司 Lieur, conjugué ligand-médicament et utilisation médicale associée
US12378314B1 (en) 2024-02-02 2025-08-05 Medicovestor, Inc. Proteins that bind folate receptor alpha including fully-human antibodies
US12258396B1 (en) 2024-02-02 2025-03-25 Medicovestor, Inc. Methods of using immunotherapeutics that bind folate receptor alpha
US12240900B1 (en) 2024-02-02 2025-03-04 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
WO2025199464A1 (fr) 2024-03-22 2025-09-25 Eisai R&D Management Co., Ltd. Conjugués anticorps-médicament anti-trop2 et procédés d'utilisation
WO2025228172A1 (fr) * 2024-04-28 2025-11-06 上海拓济医药有限责任公司 Dérivé d'éribuline, conjugué anticorps-médicament de celui-ci et utilisation médicale associée
WO2026037417A1 (fr) * 2024-08-15 2026-02-19 上海睿智医药技术有限公司 Nouvelle molécule active liée à l'éribuline, composé de molécule de toxine de lieur-médicament la contenant, et son utilisation dans un conjugué d'anticorps

Family Cites Families (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
CA2109528A1 (fr) 1991-05-01 1992-11-02 Gregory A. Prince Methode de traitement des maladies respiratoires infectieuses
EP0940468A1 (fr) 1991-06-14 1999-09-08 Genentech, Inc. Domaine variable d'un anticorps humanisé
US5622929A (en) * 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
ATE234635T1 (de) 1995-12-22 2003-04-15 Bristol Myers Squibb Co Verzweigte hydrazongruppen enthaltende kuppler
DK0885002T3 (da) 1996-03-04 2011-08-22 Penn State Res Found Materialer og fremgangsmåder til forøgelse af cellulær internalisering
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
CA2277801C (fr) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation de particules pour inhalation
CA2336139C (fr) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Grandes particules poreuses emises par un inhalateur
US6019963A (en) 1998-11-20 2000-02-01 D.S.C. Products, Inc. Deodorizing composition containing tea tree and eucalyptus oils
US7109019B2 (en) 1999-01-06 2006-09-19 The Regents Of The University Of California Gene cluster for production of the enediyne antitumor antibiotic C-1027
CN1635910A (zh) 2001-05-02 2005-07-06 普渡研究基金会 巨噬细胞介导的疾病的治疗和诊断
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7399613B2 (en) 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
EP1531846A4 (fr) 2002-02-27 2006-04-19 Us Gov Health & Human Serv Conjugues de ligand, adaptateur et agent cytotoxique, compositions associees et procedes d'utilisation relatifs
DK1545613T3 (da) * 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
JP2004119755A (ja) 2002-09-27 2004-04-15 Alps Electric Co Ltd 磁気検出素子及びその製造方法
US20040071540A1 (en) 2002-10-15 2004-04-15 Lucas Philip J. Disposable/recyclable pallet system and method
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
EP1615945B1 (fr) 2003-04-09 2011-09-28 BioGeneriX AG Methode de glycopegylation et proteines/peptides produits au moyen de ces methodes
EP1670477A2 (fr) 2003-09-18 2006-06-21 CombinatoRx, Incorporated Associations de medicaments destinees au traitement de tumeurs
US6997024B2 (en) 2003-10-01 2006-02-14 Truth Hardware Corporation Pull door lock
US20050148535A1 (en) 2003-10-30 2005-07-07 Lacasse Eric IAP nucleobase oligomers and oligomeric complexes and uses thereof
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
AU2005214331B2 (en) 2004-02-12 2011-09-15 Eisai, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
US7117807B2 (en) 2004-02-17 2006-10-10 University Of Florida Research Foundation, Inc. Dynamically modifiable polymer coatings and devices
WO2006073419A2 (fr) 2004-04-01 2006-07-13 Gang Zheng Nanoplateformes lipoproteiniques
CA2569003A1 (fr) 2004-05-07 2005-12-08 Massachusetts Institute Of Technology Procede et compositions pour traitement du cancer relatif a la reconnaissance du domaine brca1 brct de bach1 phosphoryle
CN101899026B (zh) 2004-06-03 2016-08-03 卫材R&D管理有限公司 用于制备软海绵素b的类似物的中间体
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006076100A2 (fr) 2004-12-09 2006-07-20 Eisai Co. Ltd. Criblage de l'isotype tubuline en therapie du cancer faisant appel aux analogues de l'halichondrine b
WO2006063135A2 (fr) 2004-12-09 2006-06-15 Eisai R & D Management Co., Ltd. Criblage d'isotype de tubuline en therapie du cancer, au moyen d'analogues d'hemiasterline
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
WO2007008603A1 (fr) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Composes de monomethylvaline presentant des modifications de la chaine laterale de phenylalanine au niveau de l'extremite c
GB0515025D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
US8465724B2 (en) 2005-08-19 2013-06-18 Endocyte, Inc. Multi-drug ligand conjugates
ES2382879T3 (es) 2005-09-14 2012-06-14 Ucb Pharma, S.A. Conjugado de anticuerpo - polímero de peine.
CA2632903C (fr) 2005-12-02 2015-11-24 Vianova Labs, Inc. Traitement du cancer et d'autres maladies
WO2007128884A1 (fr) 2006-05-09 2007-11-15 Oy Jurilab Ltd Gènes et marqueurs atypiques dans le diabète de type 2 et l'obésité
US20150030534A1 (en) 2013-07-26 2015-01-29 Rutgers, The State University Of New Jersey Antibody cocktails for breast cancer radioimmunotherapy
US20140037539A1 (en) 2012-07-27 2014-02-06 Rutgers, The State University Of New Jersey Antibody cocktails for breast cancer radioimmunotherapy
US8398956B2 (en) 2007-01-11 2013-03-19 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN101678124A (zh) 2007-03-14 2010-03-24 恩多塞特公司 结合配体连接的微管溶素递药缀合物
EP1977765A1 (fr) 2007-04-03 2008-10-08 Diatos Promédicaments de peptide
BRPI0817909B1 (pt) 2007-10-03 2022-06-21 Eisai R&D Management Co., Ltd Métodos de obtenção e de preparação de uma composição diastereomericamente pura, compostos, e método para produzir os referidos compostos
CA2698541C (fr) * 2007-10-19 2018-01-09 Genentech, Inc. Anticorps anti-tenb2 modifies par des cysteines et conjugues anticorps-medicament
CN101884058B (zh) 2007-10-30 2012-07-25 富士通株式会社 移动终端装置
DK2265283T3 (da) 2008-03-18 2014-10-20 Seattle Genetics Inc Auristatin-lægemiddel-linker-konjugater
EP2977468B1 (fr) 2008-03-27 2019-06-19 Vascular Biosciences, Inc. Procédés d'identification de nouveaux candidats thérapeutiques par analyse de l'expression génétique dans l'hypertension artérielle pulmonaire
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
CN102083461B (zh) * 2008-04-30 2014-09-17 伊缪诺金公司 有效的偶联物和亲水性连接体
AR072000A1 (es) 2008-06-03 2010-07-28 Abbott Lab Proteinas de union multivalentes con capacidad de unir dos o mas antigenos y usos de la misma
JP2011523853A (ja) 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
BRPI0915448A2 (pt) 2008-07-08 2015-11-10 Abbott Lab imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas
KR20110053467A (ko) 2008-09-12 2011-05-23 산텐 세이야꾸 가부시키가이샤 술폰산에스테르 구조를 도입한 페닐기를 치환기로서 갖는 신규 1,2,3,4-테트라히드로퀴녹살린 유도체를 포함하는 글루코코르티코이드 수용체 작용제
JP2012510821A (ja) 2008-12-04 2012-05-17 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
SG173705A1 (en) 2009-03-05 2011-09-29 Abbott Lab Il-17 binding proteins
US20140339088A1 (en) 2009-03-09 2014-11-20 Virginia Tech Intellectual Properties, Inc. Dielectrophoresis methods for determining a property of a plurality of cancer cells
TW201042040A (en) 2009-05-01 2010-12-01 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8686520B2 (en) * 2009-05-29 2014-04-01 International Business Machines Corporation Spin-torque magnetoresistive structures
UY32808A (es) 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
BR112012003346A2 (pt) * 2009-08-15 2016-11-16 Genentech Inc metodo de tratamento de um paciente diagnostico com cancer de mama metastico previamente tratado kit para tratamento de cancer de mama metastatico previamente tratado em um paciente humano metodo para instruir um paciente humano com cancer metodo promocional e metodo comercial
KR20120060877A (ko) 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
GB0917044D0 (en) 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
TW201119676A (en) 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UA105813C2 (uk) 2009-11-06 2014-06-25 Плексікон, Інк. Сполуки-інгібітори кіназ та фармацевтична композиція (варіанти)
BR112012018232B8 (pt) 2010-01-26 2023-01-10 Eisai R&D Man Co Ltd Compostos derivados de furo [3,2-b] pirano úteis na síntese de análogos de halicondrina b e métodos de sintetização de er-80402 e de eribulina
US8710035B2 (en) 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
CN110386876A (zh) 2010-03-24 2019-10-29 俄亥俄州立大学 用于葡萄糖转运抑制的组合物和方法
MY161302A (en) 2010-05-14 2017-04-14 Abbvie Inc IL-1 binding proteins
AU2011267106B2 (en) 2010-06-15 2015-05-14 Genmab A/S Human antibody drug conjugates against tissue factor
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP3252072A3 (fr) 2010-08-03 2018-03-14 AbbVie Inc. Immunoglobuline à double domaine variable et ses utilisations
SG187938A1 (en) 2010-08-26 2013-04-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
US9089570B2 (en) 2010-09-03 2015-07-28 Tactical Therapeutics Inc Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
WO2012031609A1 (fr) 2010-09-07 2012-03-15 Johannes Kepler Universität Linz Poly(organo)phosphazènes biodégradables, hydrosolubles et répondant au ph
WO2012065019A2 (fr) 2010-11-12 2012-05-18 Exelixis, Inc. Inhibiteurs pyridopyrimidinone de p13k alpha
WO2012065057A2 (fr) 2010-11-12 2012-05-18 Exelixis, Inc. Inhibiteurs de la phosphatidylinositol 3-kinase et leurs procédés d'utilisation
WO2012075361A2 (fr) 2010-12-02 2012-06-07 Immunomedics, Inc. Chimie click exempte de cuivre in vivo pour l'administration d'agents thérapeutiques et/ou diagnostiques
AU2011361720B2 (en) 2010-12-21 2017-04-27 Abbvie Inc. IL-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
UY33827A (es) 2010-12-22 2012-07-31 Abbott Lab Proteínas de unión a media-inmunoglobulina y sus usos
US20120195900A1 (en) 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
WO2012106559A1 (fr) 2011-02-02 2012-08-09 Translational Genomics Research Institute Biomarqueurs et leurs procédés d'utilisation
EP2675474B1 (fr) 2011-02-15 2019-01-16 Vaxiion Therapeutics, LLC Compositions thérapeutiques et procédés d'administration ciblée de molécules bioactives par des minicellules bactériennes basée sur des molécules de ciblage contenant un fragment fc et des anticorps
WO2012116277A1 (fr) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Modulateurs du récepteur cannabinoïde
EP2680839A1 (fr) * 2011-03-02 2014-01-08 Morphotek, Inc. Co-administration d'éribuline et de farletuzumab pour le traitement du cancer du sein
WO2012118978A1 (fr) 2011-03-03 2012-09-07 The Regents Of The University Of Colorado, A Body Corporate Procédés pour traiter des cancers positifs aux oncovirus
EP2966061B1 (fr) 2011-03-04 2017-05-03 Life Technologies Corporation Composés et procédés de conjugaison de biomolécules
CA2830240A1 (fr) 2011-03-15 2012-09-20 The University Of North Carolina At Chapell Hill Methodes de traitement du cancer du sein par une therapie par anthracycline
ES2731653T3 (es) 2011-03-18 2019-11-18 Eisai R&D Man Co Ltd Métodos y usos para predecir la respuesta a la eribulina
EP2508525A1 (fr) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Sels de 2,3-dihydroimidazo[1,2-C]quinazoline substitutés
US9132131B2 (en) 2011-04-21 2015-09-15 Saint Louis University Use of adenosine A3 receptor agonists for treatment of neuropathic pain
KR102179369B1 (ko) 2011-05-27 2020-11-16 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
EP2714685B1 (fr) 2011-05-27 2016-10-19 Ambrx, Inc. Compositions contenant des dérivés de dolastatine liés à des acides aminés non naturel
WO2012170640A1 (fr) 2011-06-07 2012-12-13 The Trustees Of Columbia University In The City Of New York Procédés et compositions pour traitement par une combinaison trail-médicament
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP3228325A1 (fr) 2011-06-10 2017-10-11 Mersana Therapeutics, Inc. Conjugués protéine-polymère-médicament
EP2739649B1 (fr) 2011-08-05 2017-09-27 Bioasis Technologies Inc. Fragments de p97 avec activité de transfert
EP2785687B1 (fr) 2011-11-30 2019-02-20 Sandoz AG Procédé de préparation de (3r)-2,4-di-groupe partant-3-méthylbut-1-ène
EP2791123B1 (fr) 2011-12-16 2018-07-18 Sandoz AG Procédé de préparation de dérivés de 3-((2s,5s)-4-méthylène-5- (3-oxopropyl)tétrahydrofuran-2-yl)propanol et d'intermédiaires utiles à leur préparation
EP2793947B1 (fr) 2011-12-23 2021-02-03 Innate Pharma Conjugaison enzymatique de polypeptides
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
AU2012363334B2 (en) 2011-12-29 2017-02-02 Alphora Research Inc. 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl) tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
WO2013130093A1 (fr) * 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
WO2013138371A1 (fr) 2012-03-12 2013-09-19 Merrimack Pharmaceuticals, Inc. Procédés de traitement du cancer du pancréas à l'aide de thérapies combinées comprenant un anticorps anti-erbb3
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
WO2013148337A1 (fr) 2012-03-29 2013-10-03 Altor Bioscience Corporation Procédés de traitement de la néoplasie
CN104334562A (zh) 2012-03-30 2015-02-04 阿方拉研究股份有限公司 用于制备软海绵素b的大环c1-酮类似物的合成方法及其中有用的中间体
KR20140148412A (ko) 2012-04-02 2014-12-31 메리맥 파마슈티컬즈, 인크. 단일특이적 및 이중특이적인 항-igf-1r 및 항-erbb3 항체의 용량 및 투여
BR112014028396A2 (pt) 2012-05-15 2018-05-29 Diatech Oncology processo de isolamento/purificação de célula de tumor e métodos para uso da mesma
HK1208216A1 (en) 2012-05-15 2016-02-26 Concortis Biosystems, Corp Drug-conjugates, conjugation methods, and uses thereof
KR102143664B1 (ko) 2012-06-07 2020-08-11 암브룩스, 인코포레이티드 전립선 특이적 막 항원 항체 약물 접합체
KR101915942B1 (ko) 2012-06-08 2018-11-06 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
SG11201408494UA (en) 2012-06-19 2015-02-27 Ambrx Inc Anti-cd70 antibody drug conjugates
EP2866795A4 (fr) 2012-06-29 2016-01-27 Univ New York State Res Found Agents poly-énoliques de liaison au zinc (pezbin) favorisant activement l'inactivation de cellules souches cancéreuses et potentialisant des substances médicamenteuses anti-tumorales cytotoxiques
US20140037620A1 (en) 2012-06-29 2014-02-06 British Columbia Cancer Agency Branch Methods of Treating Breast Cancer with Gemcitabine Therapy
HUE048574T2 (hu) 2012-07-12 2020-08-28 Hangzhou Dac Biotech Co Ltd Sejthez kötõdõ molekulák citotoxikus szerekkel képzett konjugátumai
US20140069822A1 (en) 2012-09-10 2014-03-13 Antec Leyden B.V. Electrochemical reduction of disulfide bonds in proteinaceous substances and electrochemical cell for carrying out such reduction
WO2014047199A1 (fr) 2012-09-19 2014-03-27 The Research Foundation For The State University Of New York Nouveaux promédicaments pour une thérapie anticancéreuse sélective
MX369999B (es) 2012-10-04 2019-11-28 Ab Science Uso de masitinib en combinación con gemcitabina para el tratamiento de cáncer pancreatico en subpoblaciones de pacientes identificados en base al factor predictor de la intensidad de dolor.
EP2906712A1 (fr) 2012-10-10 2015-08-19 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Procédés et moyens de prédiction de résistance à un traitement anti-cancer
WO2014063443A1 (fr) 2012-10-22 2014-05-01 Zhang Yuliang Procédé de travail thermique auto-refroidissant
SI2911699T2 (sl) 2012-10-23 2026-01-30 Synaffix B.V. Modificirano protitelo, protitelo-konjugat in proces za njihovo pripravo
CA2890569C (fr) 2012-11-05 2019-03-05 Pfizer Inc. Analogues de spliceostatine
CA2891280C (fr) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Lieurs hydrophiles et leurs utilisations pour la conjugaison de medicaments a des molecules se liant aux cellules
SG11201504184PA (en) 2012-12-03 2015-06-29 Calithera Biosciences Inc Treatment of cancer with heterocyclic inhibitors of glutaminase
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
WO2014093379A1 (fr) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Composés auristatine et leurs conjugués
AU2013359506B2 (en) 2012-12-10 2018-05-24 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP2931316B1 (fr) 2012-12-12 2019-02-20 Mersana Therapeutics, Inc. Conjugués hydroxy-polymère-médicament-protéine
US20150314007A1 (en) 2012-12-21 2015-11-05 Glykos Finland Oy Linker-payload molecule conjugates
US20150182634A1 (en) 2012-12-28 2015-07-02 Cody P. Coyne Molecular Design and Chemical Synthesis of Pharmaceutical-Ligands and Pharmaceutical-Pharmaceutical Analogs with Multiple Mechanisms of Action
WO2014113794A2 (fr) 2013-01-19 2014-07-24 New York University Oligooxopipérazines pour la réactivation du p53
WO2014113792A1 (fr) 2013-01-19 2014-07-24 New York University Peptides et peptidomimétiques de substitution à liaison hydrogène pour la réactivation du p53
US20140220112A1 (en) 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes
US20140220111A1 (en) 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Remote loading of sparingly water-soluble drugs into liposomes
US9849193B2 (en) 2013-02-08 2017-12-26 University Of Louisville Research Foundation, Inc. Nanoparticles for drug delivery
EP2958568B1 (fr) 2013-02-22 2020-03-04 University Of Houston Phosphaplatines en tant qu'agents neuroprotecteurs
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
EP2968585B1 (fr) * 2013-03-13 2018-07-18 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
WO2015073072A1 (fr) 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-méthylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
HUE044238T2 (hu) 2013-03-13 2019-10-28 Oncoceutics Inc 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-hexahidroimidazo[l,2-a]pirido[4,3-d]pirimidin-5(3h)-on rák kezelésénél történõ alkalmazásra
US20160022829A1 (en) 2013-03-14 2016-01-28 Mersana Therapeutics, Inc. Tubulysin compounds and conjugates thereof
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
US20160038456A1 (en) 2013-03-14 2016-02-11 University Of Florida Research Foundation, Incorporated Regulation of cancer using natural compounds and/or diet
AU2014228489B2 (en) 2013-03-15 2018-11-15 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US9295731B2 (en) 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
WO2014168721A2 (fr) 2013-04-12 2014-10-16 Tufts Medical Center Procédés et systèmes pour mettre au point et/ou caractériser des agents ligands lipidés solubles
EP2988786A4 (fr) 2013-04-22 2016-12-21 Avelas Biosciences Inc Compositions et procédés d'utilisation pour l'administration sélective de médicaments
GB2513405A (en) 2013-04-26 2014-10-29 Adc Biotechnology Ltd Method of synthesising ADCs using affinity resins
SI2991683T1 (sl) 2013-05-02 2020-01-31 Glykos Finland Oy Konjugati glikoproteina ali glikana s toksično obremenitvijo
WO2014183211A1 (fr) 2013-05-15 2014-11-20 Alphora Research Inc. Dérivés de 3-((2s,5s)-4-méthylène-5-(3-oxopropyl)tétrahydrofuran-2-yl)propanol, leur préparation et intermédiaires utiles correspondants
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
WO2014197854A1 (fr) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Nouveaux lieurs pour conjugués anticorps-médicament et composés connexes, compositions, et procédés d'utilisation
US20140363454A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Antibody-Drug Conjugates, Compositions and Methods of Use
EP3010547B1 (fr) 2013-06-20 2021-04-21 Innate Pharma Conjugaison enzymatique de polypeptides
CN105517577A (zh) 2013-06-21 2016-04-20 先天制药公司 多肽的酶促偶联
WO2014206466A1 (fr) 2013-06-26 2014-12-31 Afg Technologies S.À.R.L Criblage, diagnostic, pronostic et traitement du cancer des ovaires
AU2014286880B2 (en) 2013-07-03 2017-12-14 Sandoz Ag Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein including intermediates containing -SO2-(p-TOLYL) groups
WO2015017729A1 (fr) 2013-07-31 2015-02-05 Virginia Tech Intellectual Properties, Inc. Procédés de diélectrophorèse pour déterminer une propriété d'une pluralité de cellules cancéreuses
US20160166637A1 (en) 2013-08-02 2016-06-16 Virginia Tech Intellectual Properties, Inc. Methods of treating a cancer through targeted disruption of alpha connexin 43-zonula occludens-1 (zo-1) interaction
JP2016538318A (ja) 2013-08-28 2016-12-08 ステムセントリックス， インコーポレイテッド 新規ｓｅｚ６モジュレーターおよび使用方法
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
WO2015031698A1 (fr) 2013-08-28 2015-03-05 Stem Centrx, Inc. Procédés de conjugaison d'anticorps régiospécifiques et compositions
JP2016537010A (ja) 2013-09-09 2016-12-01 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ 予後を予測するための方法及びキット、並びに、放射線照射療法を用いた乳癌の治療方法及びキット
WO2015038426A1 (fr) 2013-09-13 2015-03-19 Asana Biosciences, Llc Lieurs auto-immolables contenant des dérivés d'acide mandélique, conjugués médicament-ligand pour thérapies ciblées, et leurs utilisations
US20150093331A1 (en) 2013-10-01 2015-04-02 OncoLock Co., Ltd. Biomarkers for breast cancer
US9878049B2 (en) 2013-10-09 2018-01-30 The University Of Akron High drug loading system to co-deliver anticancer drugs and nucleic acids for cancer therapy
KR102572149B1 (ko) 2013-10-11 2023-08-30 아사나 바이오사이언시스 엘엘씨 단백질-폴리머-약물 접합체
CA2925393C (fr) 2013-10-11 2023-03-07 Dimiter Dimitrov Anticorps tem8 et leur utilisation
CA2926586C (fr) 2013-10-11 2020-04-07 Mersana Therapeutics, Inc. Echafaudage polymere fonde sur le phf pour la liberation de medicaments a cible definie
JP6684706B2 (ja) 2013-10-21 2020-04-22 ヘモシアー・リミテッド・ライアビリティ・カンパニーＨｅｍｏＳｈｅａｒ， ＬＬＣ 腫瘍微細環境のための試験管内モデル
HUE049387T2 (hu) 2013-11-04 2020-09-28 Eisai R&D Man Co Ltd A halichondrin B analógjainak szintézisében hasznos makrociklizációs reakciók és köztitermékek
CA2929715A1 (fr) 2013-11-07 2015-05-14 Deciphera Pharmaceuticals, Llc Methodes d'inhibition de la kinase tie2 utiles dans le traitement du cancer
US9457019B2 (en) 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
KR20250006309A (ko) 2013-11-15 2025-01-10 온코슈틱스 인코포레이티드 7-벤질-4-(2-메틸벤질)-2,4,6,7,8,9-헥사하이드로이미다조[1,2-a]피리도[3,4-e]피리미딘-5(1H)-온,이의 염 및 이의 용도
CA3178867A1 (fr) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Composes hydrazinyl-pyrrolo et procedes de production d'un conjugue
SG10201805024YA (en) 2013-12-06 2018-07-30 Eisai R&D Man Co Ltd Methods useful in the synthesis of halichondrin b analogs
US20170020817A1 (en) 2013-12-19 2017-01-26 Luminus Biosciences, Inc. Solid nanoparticle formulation of microtuble inhibitors with reduced ostwald repening for oral administration
AU2015205753A1 (en) 2014-01-10 2016-07-21 Birdie Biopharmaceuticals Inc. Compounds and compositions for treating HER2 positive tumors
CA2939120A1 (fr) 2014-01-10 2015-07-16 Rgenix, Inc. Agonistes du recepteur x du foie et leurs utilisations
WO2015106094A1 (fr) 2014-01-10 2015-07-16 Atossa Genetics Inc. Procédés et compositions transpapillaires pour le dignostic et le traitement de maladies du sein
CN104784699B (zh) 2014-01-20 2019-05-03 博瑞生物医药（苏州）股份有限公司 叶酸受体结合配体-药物偶联物
BR112016017010A2 (pt) * 2014-02-03 2017-10-03 Nat Cancer Ct Anticorpo monoclonal de fator antitecido
CA3151947A1 (fr) 2014-02-03 2015-08-06 Eidgenoessische Technische Hochschule Zuerich Conjugues de medicament a faible poids moleculaire servant a la liaison a l'anhydrase ix carbonique
EP2913064A1 (fr) 2014-02-26 2015-09-02 celares GmbH Conjugués de lieurs de médicaments ramifiés pour le couplage à des molécules biologiques de ciblage
TW201617326A (zh) 2014-03-06 2016-05-16 Ａｌｐｈｏｒａ研發股份有限公司 （ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物
AU2015228860A1 (en) 2014-03-13 2016-09-08 F. Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
US9260478B2 (en) * 2014-04-04 2016-02-16 Shanghui Hu Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis
WO2015157471A1 (fr) 2014-04-08 2015-10-15 The Methodist Hospital Compositions inhibitrices d'inos et leur utilisation comme agents thérapeutiques de cancer du sein
AU2015247806A1 (en) 2014-04-14 2016-10-27 Endocyte, Inc. Drug delivery conjugates for treating resistant cancer and for use in combination therapy
WO2015161247A1 (fr) * 2014-04-17 2015-10-22 Igenica Biotherapeutics, Inc. Anticorps anti-c16orf54 humanisés et leurs méthodes d'utilisation
HUE047952T2 (hu) * 2014-04-25 2020-05-28 Pf Medicament Ellenanyag-drog konjugátum és alkalmazása rák kezelésében történõ alkalmazásra
KR101628872B1 (ko) * 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
TWI695011B (zh) * 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
US9808528B2 (en) * 2014-06-18 2017-11-07 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates and methods of using same
WO2016008112A1 (fr) * 2014-07-16 2016-01-21 Medshine Discovery Inc. Lieurs et application à des conjugués anticorps-médicament (acd) associée
EP3069734A1 (fr) * 2015-03-17 2016-09-21 Exiris S.r.l. Conjugués anticorps-médicament à base de cryptophycine avec de nouveaux lieurs auto-immolateurs
US10975112B2 (en) * 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
WO2015151079A2 (fr) 2015-06-20 2015-10-08 Hangzhou Dac Biotech Co, Ltd Analogues d'auristatine et leur conjugués avec des molécules de liaison cellulaire

Also Published As

Publication number Publication date
MY199595A (en) 2023-11-08
MX2018010562A (es) 2019-02-20
SG11201806515RA (en) 2018-09-27
EP3423105A1 (fr) 2019-01-09
JP6599019B2 (ja) 2019-10-30
AR121301A2 (es) 2022-05-04
JP2021185176A (ja) 2021-12-09
JP6870051B2 (ja) 2021-05-12
IL261428B1 (en) 2025-06-01
AU2026201384A1 (en) 2026-03-12
DK3423105T3 (da) 2021-07-26
RU2021125492A (ru) 2022-04-05
PE20231050A1 (es) 2023-07-11
CO2018008667A2 (es) 2018-08-31
SI3423105T1 (sl) 2021-12-31
PH12018501847A1 (en) 2019-05-15
WO2017151979A1 (fr) 2017-09-08
JP2019516664A (ja) 2019-06-20
CN114272389B (zh) 2023-04-18
CN114272389A (zh) 2022-04-05
MX2023003808A (es) 2023-04-12
IL261428A (en) 2018-10-31
JP2024174991A (ja) 2024-12-17
KR102445255B1 (ko) 2022-09-22
PE20231049A1 (es) 2023-07-11
CL2021000049A1 (es) 2021-05-28
RU2754369C2 (ru) 2021-09-01
AU2023285804A1 (en) 2024-01-18
MA45280B1 (fr) 2021-08-31
AU2023285804B2 (en) 2025-12-18
SMT202100416T1 (it) 2021-09-14
RU2018134331A3 (fr) 2020-08-14
KR20220101204A (ko) 2022-07-19
CL2018002456A1 (es) 2018-12-21
AR121302A2 (es) 2022-05-04
RS62108B1 (sr) 2021-08-31
HRP20211125T1 (hr) 2021-10-15
PT3423105T (pt) 2021-07-19
US20170252458A1 (en) 2017-09-07
KR102456433B1 (ko) 2022-10-19
US20200297860A1 (en) 2020-09-24
US20230398228A1 (en) 2023-12-14
KR102702620B1 (ko) 2024-09-05
SG10202007520WA (en) 2020-09-29
JP2020128413A (ja) 2020-08-27
UA125024C2 (uk) 2021-12-29
MX2023003806A (es) 2023-04-12
BR112018067379A2 (pt) 2019-01-15
JOP20210073A1 (ar) 2023-01-30
IL261428B2 (en) 2025-10-01
IL320940A (en) 2025-07-01
TW201800110A (zh) 2018-01-01
ES2880402T3 (es) 2021-11-24
CA3013791A1 (fr) 2017-09-08
US10548986B2 (en) 2020-02-04
PL3423105T3 (pl) 2021-10-25
NZ744808A (en) 2024-04-26
MD3423105T2 (ro) 2021-10-31
KR20220101203A (ko) 2022-07-19
KR20180115330A (ko) 2018-10-22
JOP20170053B1 (ar) 2021-08-17
HUE054726T2 (hu) 2021-09-28
TWI825834B (zh) 2023-12-11
AU2017225982A1 (en) 2018-08-16
PE20181953A1 (es) 2018-12-17
IL292946B1 (en) 2024-07-01
AR107787A1 (es) 2018-06-06
CN114191428B (zh) 2024-09-24
JOP20210074A1 (ar) 2023-01-30
NZ785232A (en) 2025-05-30
MY189113A (en) 2022-01-26
TW202408592A (zh) 2024-03-01
TWI772288B (zh) 2022-08-01
JP7556086B2 (ja) 2024-09-25
EP3423105B1 (fr) 2021-05-05
CY1124628T1 (el) 2022-07-22
TW202241524A (zh) 2022-11-01
IL292946A (en) 2022-07-01
CN114191563A (zh) 2022-03-18
JP7254861B2 (ja) 2023-04-10
CN108883198A (zh) 2018-11-23
JP2020019787A (ja) 2020-02-06
CN108883198B (zh) 2022-08-09
US10322192B2 (en) 2019-06-18
JP2023082096A (ja) 2023-06-13
RU2018134331A (ru) 2020-04-02
AU2017225982B2 (en) 2023-10-05
EP3824909A1 (fr) 2021-05-26
LT3423105T (lt) 2021-09-10
IL292946B2 (en) 2024-11-01
TWI871094B (zh) 2025-01-21
CN114191428A (zh) 2022-03-18
CL2021000048A1 (es) 2021-05-28
MX2023003809A (es) 2023-04-12
KR20240007722A (ko) 2024-01-16
US20180193478A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
MA45280A (fr) Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation
MA48709A (fr) Conjugués de médicament à base de silicium et leurs procédés d'utilisation
EP3493676A4 (fr) Compositions antimicrobiennes à base de polymère et leurs procédés d'utilisation
EP3436048A4 (fr) Néoantigènes et leurs procédés d'utilisation
FR24C1044I2 (fr) Anticorps anti-c5 et leurs procédés d'utilisation
MA47499A (fr) Anticorps anti-tau et leurs procédés d'utilisation
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
MA49520A (fr) Agents de comblement tissulaire à base de soie-acide hyaluronique et leurs procédés d'utilisation
EP3416634A4 (fr) Agents immunomodulateurs et leurs procédés d'utilisation
EP3472200A4 (fr) Anticorps anti-myostatine et leurs procédés d'utilisation
MA46566A (fr) Oxystérols et leurs procédés d'utilisation
EP3383914A4 (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
MA46565A (fr) Oxystérols et leurs procédés d'utilisation
MA44740A (fr) Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation
EP3463440A4 (fr) Compositions de vaccins à base de néo-épitopes et leurs méthodes d'utilisation
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
EP3436061A4 (fr) Compositions de conjugués saccharide-polypeptide polymérisables et leurs procédés d'utilisation
EP3510040A4 (fr) Inhibiteurs d'éctonucléotidase et leurs procédés d'utilisation
EP3400097A4 (fr) Mélangeurs à bifurcation et leurs procédés d'utilisation et de fabrication
MA55097A (fr) Oxystérols et leurs procédés d'utilisation
EP3436476A4 (fr) Anticorps anti-ryk et leurs procédés d'utilisation
EP3442584A4 (fr) Combinaisons de conjugués anticorps-médicament à base de pbd et d'inhibiteurs de bcl-2
EP3435956A4 (fr) Compositions photo-stabilisées et leurs procédés d'utilisation
HUE052468T2 (hu) Arginázgátlók és terápiás alkalmazásaik
EP3319612A4 (fr) Oxystérols et leurs procédés d'utilisation